Mimic human complexity in a Beat to revolutionize the drug development

BiomimX Beating organs-on-chips (OoC) are in vitro miniaturized and living replica of human organs and diseases,building upon cutting-edge technologies and human cells.

Beating OoC provide a faithful replication of native humanphysiology integrating miniaturized 3D cell culture techniques, mechanical stimulation (uBeat®) and electrical recordingcapabilities (uSense).

BiomimX’s proprietary key technology (uBeat®) supports 3D human cell cultures and integrates acontrolled and tunable mechanical stimulation system. uBeat® leads to the generation of mature and functional miniaturizedreplication of human organs adequate to test compounds toxicity/functionality in a high-throughput fashion.

Integration ofuSense allows real-time evaluation of clinically relevant parameters from the established beating models.

BiomimX’sBeating OoC represent a safer, more efficient and faster alternative to poorly predictable preclinical models to date available inthe drug discovery pipeline (DDP).

BiomimX already demonstrated the validity of its Beating OoC models in two critical fields ofthe drug discovery pipeline: uHeart (human beating heart-on-chip) has been applied as early predictor of drug functionalcardiotoxicity, uKnee (first in vitro model of human OA) has shown its predictive potential for the discovery of new targets foran unmet pathology.Also thanks to the contribution of Women TechEU programme, BiomimX aims at demonstrating the unprecedented potential of its disruptive innovation in reshaping the market of drug development, by i) boosting technological aspects (i.e. through an intensive industrialization process of BiomimX patented technologies) and ii) proving the versatility of its innovation and its capacity to adapt to a manifold of indications and market spaces.

In line with the 3R principle, BiomimX final vision is to reduce and eventually replace animal experimentations within the next 15-years.